Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Boundless Bio, Inc. is a clinical-stage oncology company focused on developing therapies targeting extrachromosomal DNA (ecDNA), a key driver of oncogene amplification in cancer. Its proprietary platform identifies vulnerabilities in ecDNA biology to create small molecule ecDNA-directed therapeutics (ecDTx). The company's lead drug, BBI-355, a CHK1 inhibitor, aims to treat ecDNA-driven cancers resistant to existing therapies, addressing a significant unmet medical need across multiple tumor types.
This description was generated via AI from an annual report. Updated about 1 year ago.